Fulcrum Therapeutics Inc. (FULC) Tops Q3 EPS by 5c

Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q3 EPS of ($0.39), $0.05 better than the analyst estimate of ($0.44). Revenue for the quarter came in at $760 thousand versus the consensus estimate of $1.05 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Schwab's May activity shows margin loans nearly double
• Aspire Biopharma to acquire automotive supplier for $30 million